Summary of significant treatment × time effect. by Wensheng Xiao (16557866)

Summary of significant single-arm time effect. by Wensheng Xiao (16557866)

Lymphocytes decreased in mouse pneumonia model. by Qi Xu (134661)

Mean case duration before and after intervention (t-statistic = -3.35, p <i>< </i>0.001), indicating a statistically significant difference in means. by Mohammad Bakhtiari (11838264)

BA attenuated the decrease in the expression of ZO-1 and Occludin induced by LPS in Caco2 cells. by Luqiong Liu (11537092)

Average mean decrease Gini across 100 partitions for the top 10 most important variables for binary mixed model and random forest. by Helal El-Zaatari (20442243)

Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque mean size. by Francesca Catto (21253435)

AdMSC-EVs enhanced colony formation and migration of LECs and decreased proliferation. by Xiaoqin Li (1399105)

miRNA 221 improved left ventricular contractile function in MIRI mice. by Hongyu Li (1332669)

Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. by Luqiong Liu (11537092)

“…The values are expressed as the means ± SDs and were analyzed according to the variance of the factorial design. **, *** and ****denote <i>p</i> < 0.01, < 0.001 and < 0.0001, respectively; ns  =  not significant.…”

Y-27632 synergized with BA to alleviate the decrease in the expression of and abnormal localization of ZO-1 and Occludin in LPS-induced Caco2 cells. by Luqiong Liu (11537092)

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects: